The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Baritaki, S., Suzuki, E., Umezawa, K., Spandidos, D. A., Berenson, J. R., Daniels‐Wells, T. R., Penichet, M. L., Jazirehi, A. R., Palladino, M. A., & Bonavida, B. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.6199 · Cited by 78
RetractedThe ubiquitin-proteasome pathway: on protein death and cell life
Ciechanover, A. (1998) · The EMBO Journal · doi:10.1093/emboj/17.24.7151 · Cited by 1,426
Proteasome inhibitors: from research tools to drug candidates
Kisselev, A. F., & Goldberg, A. L. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00056-4 · Cited by 1,184
Feling, R. H., Buchanan, G. O., Mincer, T. J., Kauffman, C. A., Jensen, P. R., & Fenical, W. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200390115 · Cited by 1,057
The development of proteasome inhibitors as anticancer drugs
Adams, J. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00120-5 · Cited by 781
Kuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W. B., Chanan-Khan, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065888 · Cited by 768
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Treon, S. P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202445099 · Cited by 741
Chauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.013 · Cited by 694 · cited 3×
“), Abstract 1445 52 Chauhan, D. et al. (2008) Combination of a novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vivo synergistic cytotoxicity in multiple myeloma.”
InfluentialAntitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Demo, S. D., Kirk, C. J., Aujay, M. A., Buchholz, T. J., Dajee, M., Ho, M. N., Jiang, J., Laidig, G. J., Lewis, E. R., Parlati, F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4086 · Cited by 678
Drug discovery in the ubiquitin–proteasome system
Nalepa, G., Rolfe, M., & Harper, J. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2056 · Cited by 608
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets
Bedford, L., Lowe, J., Dick, L. R., Mayer, R. J., & Brownell, J. E. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3321 · Cited by 563
Self-citationProteolytic networks in cancer
Mason, S. D., & Joyce, J. A. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.12.002 · Cited by 552
Proteasome inhibitors in multiple myeloma: 10 years later
Moreau, P., Richardson, P. G., Cavo, M., Orlowski, R. Z., San Miguel, J. F., Palumbo, A., & Harousseau, J.-L. (2012) · Blood · doi:10.1182/blood-2012-04-403733 · Cited by 490
Arastu-Kapur, S., Anderl, J. L., Kraus, M., Parlati, F., Shenk, K. D., Lee, S. J., Muchamuel, T., Bennett, M. K., Driessen, C., Ball, A. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1950 · Cited by 408
Targeting ER stress induced apoptosis and inflammation in cancer
Verfaillie, T., Garg, A. D., & Agostinis, P. (2013) · Cancer Letters · doi:10.1016/j.canlet.2010.07.016 · Cited by 396
Boronic acids in medicinal chemistry: anticancer, antibacterial and antiviral applications
Trippier, P. C., & McGuigan, C. (2010) · MedChemComm · doi:10.1039/c0md00119h · Cited by 346
Building and remodelling Cullin–RING E3 ubiquitin ligases
Lydeard, J. R., Schulman, B. A., & Harper, J. W. (2013) · The EMBO Reports · doi:10.1038/embor.2013.173 · Cited by 327
Boronic Esters in Asymmetric Synthesis
Matteson, D. S. (2013) · The Journal of Organic Chemistry · doi:10.1021/jo4013942 · Cited by 323
Chauhan, D., Tian, Z., Zhou, B., Kuhn, D., Orlowski, R., Raje, N., Richardson, P., & Anderson, K. C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0476 · Cited by 316
Fricker, L. D. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023603 · Cited by 309
Boron Chemicals in Diagnosis and Therapeutics
Das, B. C., Thapa, P., Karki, R., Schinke, C., Das, S., Kambhampati, S., Banerjee, S. K., Van Veldhuizen, P., Verma, A., Weiss, L. M., et al. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.38 · Cited by 279
Dou, Q., & Zonder, J. (2014) · Current Cancer Drug Targets · doi:10.2174/1568009614666140804154511 · Cited by 275
Shien, K., Toyooka, S., Yamamoto, H., Soh, J., Jida, M., Thu, K. L., Hashida, S., Maki, Y., Ichihara, E., Asano, H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4136 · Cited by 267
Management of treatment-emergent peripheral neuropathy in multiple myeloma
Richardson, P. G., Delforge, M., Beksac, M., Wen, P., Jongen, J. L., Sezer, O., Terpos, E., Munshi, N., Palumbo, A., Rajkumar, S. V., et al. (2012) · Leukemia · doi:10.1038/leu.2011.346 · Cited by 253
The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug Target
Cromm, P. M., & Crews, C. M. (2017) · ACS Central Science · doi:10.1021/acscentsci.7b00252 · Cited by 136
NFκB/p53 crosstalk—a promising new therapeutic target
Schneider, G., & Krämer, O. H. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.10.003 · Cited by 87
New orally active proteasome inhibitors in multiple myeloma
Allegra, A., Alonci, A., Gerace, D., Russo, S., Innao, V., Calabrò, L., & Musolino, C. (2014) · Leukemia Research · doi:10.1016/j.leukres.2013.10.018 · Cited by 74
Metadata
- Authors
- Dick, L. R., & Fleming, P. E.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2010-03
- Volume
- 15
- Issue
- 5-6
- Pages
- 243-249
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2091378741
- Cited by
- 273
- References
- 41
- FWCI
- 11.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.